Effect of Six Months of Treatment with V0191 in Patients with Suspected Prodromal Alzheimer’s Disease
The objective of this study was to assess the clinical efficacy and safety of a novel pro-cholinergic drug (V0191) in patients with prodromal AD.
Read lessons learned for Alzheimer’s disease research of pro-cholinergic drugs
Published in the Journal of Alzheimer’s Disease, this study found no statistically significant differences in cognitive function between the novel pro-cholinergic drug V0191 and placebo. However, lessons can be learned from several design features that may have hindered this Alzheimer’s disease research study, including insufficient powering to assess changes in cognition over time, a relatively short duration of treatment, and the lack of validated clinical trial measures designed to assess the prodromal AD population.
Questions about an upcoming Alzheimer’s Clinical Trial?
(Click to Enlarge Pages)